Literature DB >> 8281615

Vascular permeability factor (VPF, VEGF) in tumor biology.

D R Senger1, L Van de Water, L F Brown, J A Nagy, K T Yeo, T K Yeo, B Berse, R W Jackman, A M Dvorak, H F Dvorak.   

Abstract

Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine expressed and secreted at high levels by many tumor cells of animal and human origin. As secreted by tumor cells, VPF/VEGF is a 34-42 kDa heparin-binding, dimeric, disulfide-bonded glycoprotein that acts directly on endothelial cells (EC) by way of specific receptors to activate phospholipase C and induce [Ca2+]i transients. Two high affinity VPF/VEGF receptors, both tyrosine kinases, have thus far been described. VPF/VEGF is likely to have a number of important roles in tumor biology related, but not limited to, the process of tumor angiogenesis. As a potent permeability factor, VPF/VEGF promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix. This matrix promotes the ingrowth of macrophages, fibroblasts, and endothelial cells. Moreover, VPF/VEGF is a selective endothelial cell (EC) growth factor in vitro, and it presumably stimulates EC proliferation in vivo. Furthermore, VPF/VEGF has been found in animal and human tumor effusions by immunoassay and by functional assays and very likely accounts for the induction of malignant ascites. In addition to its role in tumors, VPF/VEGF has recently been found to have a role in wound healing and its expression by activated macrophages suggests that it probably also participates in certain types of chronic inflammation. VPF/VEGF is expressed in normal development and in certain normal adult organs, notably kidney, heart, adrenal gland and lung. Its functions in normal adult tissues are under investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8281615     DOI: 10.1007/BF00665960

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  79 in total

1.  The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB.

Authors:  J Wilting; B Christ; H A Weich
Journal:  Anat Embryol (Berl)       Date:  1992-08

Review 2.  Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation.

Authors:  H F Dvorak; J A Nagy; B Berse; L F Brown; K T Yeo; T K Yeo; A M Dvorak; L van de Water; T M Sioussat; D R Senger
Journal:  Ann N Y Acad Sci       Date:  1992-12-04       Impact factor: 5.691

3.  Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration.

Authors:  N Lanir; P S Ciano; L Van de Water; J McDonagh; A M Dvorak; H F Dvorak
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

4.  The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma.

Authors:  J C Underwood; I Carr
Journal:  J Pathol       Date:  1972-07       Impact factor: 7.996

5.  Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.

Authors:  V Costantini; L R Zacharski; V A Memoli; W Kisiel; B J Kudryk; S M Rousseau
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

6.  Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice.

Authors:  J A Nagy; K T Herzberg; E M Masse; G P Zientara; H F Dvorak
Journal:  Cancer Res       Date:  1989-10-01       Impact factor: 12.701

7.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules.

Authors:  H F Dvorak; J A Nagy; J T Dvorak; A M Dvorak
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

8.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

Authors:  C de Vries; J A Escobedo; H Ueno; K Houck; N Ferrara; L T Williams
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

9.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels.

Authors:  H F Dvorak; T M Sioussat; L F Brown; B Berse; J A Nagy; A Sotrel; E J Manseau; L Van de Water; D R Senger
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

10.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing.

Authors:  L F Brown; K T Yeo; B Berse; T K Yeo; D R Senger; H F Dvorak; L van de Water
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  182 in total

1.  RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins.

Authors:  K J Bayless; R Salazar; G E Davis
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 3.  New paradigm for vessel intravasation by tumor cells.

Authors:  Noel Weidner
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

4.  Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Authors:  Sung-Suk Chae; Walid S Kamoun; Christian T Farrar; Nathaniel D Kirkpatrick; Elisabeth Niemeyer; Annemarie M A de Graaf; A Gregory Sorensen; Lance L Munn; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

5.  Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.

Authors:  G Zhang; Y Wang; Y Zhang; X Wan; J Li; K Liu; F Wang; K Liu; Q Liu; C Yang; P Yu; Y Huang; S Wang; P Jiang; Z Qu; J Luan; H Duan; L Zhang; A Hou; S Jin; T-C Hsieh; E Wu
Journal:  Curr Mol Med       Date:  2012-02       Impact factor: 2.222

6.  Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

Authors:  Sho-ichi Yamagishi; Riichiro Abe; Yosuke Inagaki; Kazuo Nakamura; Hiroshi Sugawara; Daisuke Inokuma; Hideki Nakamura; Tadamichi Shimizu; Masayoshi Takeuchi; Akihiko Yoshimura; Richard Bucala; Hiroshi Shimizu; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy.

Authors:  Sophia Ran; Xianming Huang; Amber Downes; Philip E Thorpe
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

8.  VEGF localisation in diabetic retinopathy.

Authors:  M Boulton; D Foreman; G Williams; D McLeod
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

9.  Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis.

Authors:  Fengyun Dong; Xia Zhou; Changsheng Li; Suhua Yan; Xianming Deng; Zhiqun Cao; Liqun Li; Bo Tang; Thaddeus D Allen; Ju Liu
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.

Authors:  R M Tuder; B E Flook; N F Voelkel
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.